A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Sibutramine D6 | CAS 1216544-25-0 - Request Quote

Picture of Sibutramine D6

Sibutramine D6

SZ CAT No:SZ-S022D01
CAS No
1216544-25-0
Mol.F.
C17H20D6ClN
Mol.Wt.
285.9
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Sibutramine D6 is chemically 1-(1-(4-Chlorophenyl)cyclobutyl)-3-methyl-N,N-bis(methyl-d3)butan-1-amine. Sibutramine D6 is supplied with detailed characterization data compliant with regulatory guideline. Sibutramine D6 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Sibutramine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 1216544-25-0

Purchase 1216544-25-0

Order 1216544-25-0

Enquire 1216544-25-0

price of 1216544-25-0

1216544-25-0 Supplier

1216544-25-0 Manufacturer

1216544-25-0 Exporter

buy high quality Sibutramine D6

Purchase Sibutramine D6

Sibutramine D6 suppliers

Sibutramine D6 manufacturers

Sibutramine D6 price

Order Sibutramine D6

Enquire Sibutramine D6

Sibutramine D6 cost

Sibutramine D6 Supplier

Sibutramine D6 Distributor

Sibutramine D6 for Method Validation

Sibutramine Reference Standard

Sibutramine D6 for ANDA Filing

Sibutramine D6 for Forced Degradation Studies

Sibutramine D6 Identification Standards

Sibutramine D6 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,